ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24AUG813

HIV-Associated Immune Dysfunction and Hematological Abnormalities: A Detailed Examination of Pathophysiology and Clinical Implications

Zakaria EL KODMIRI[1*]
Immunopathology-Immunotherapy-Immunomonitoring Laboratory, Faculty of Medicine,
Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco
Department of Hematology, Cheikh Khalifa Ibn Zaid International University Hospital, Casablanca, Morocco

Dr. Bouchra Ghazi[2] (Professor)
Immunopathology-Immunotherapy-Immunomonitoring Laboratory, Faculty of Medicine,
Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco
Mohammed VI International University Hospital, Bouskoura, Morocco

Dr. Abdelati Ouamani[3] (Professor)
Institute of Nursing Professions and Health Techniques (ISPITS), Marrakech, Morocco

Dr. Maryame Ahnach[4] (Professor)
Immunopathology-Immunotherapy-Immunomonitoring Laboratory, Faculty of Medicine,
Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco
Department of Hematology, Cheikh Khalifa Ibn Zaid International University Hospital, Casablanca, Morocco

Corresponding Author:- Zakaria EL KODMIRI[*1]

Abstract:- Human Immunodeficiency Virus (HIV) exerts profound effects on both the immune and hematological systems, leading to a range of complications that significantly influence patient outcomes and quality of life. This review examines the intricate interplay between HIV infection, immune system dysfunction, and hematological abnormalities. We detail the mechanisms underlying these complications, including the direct impact of HIV on CD4+ T lymphocytes, the persistent immune activation observed despite antiretroviral therapy (ART), and the diverse etiologies of HIV-associated anemia, thrombocytopenia, and leukopenia. Additionally, we address the clinical implications of these issues, emphasizing their role in disease progression and the current therapeutic approaches. This review highlights the imperative for continued research and the advancement of integrated care strategies to enhance long-term outcomes for individuals living with HIV.

Keywords:- *HIV; Immune Dysfunction; Hematological Abnormalities; CD4+ T Lymphocytes; Antiretroviral Therapy (ART); Chronic Immune Activation; Anemia; Thrombocytopenia; Leukopenia; Pathophysiology; Clinical Implications; Inflammation; Opportunistic Infections.*

I. INTRODUCTION

Human Immunodeficiency Virus (HIV) remains one of the foremost global health challenges, with approximately 39 million individuals living with the virus as of 2023 [1]. Despite considerable advancements in treatment, notably through the widespread adoption of antiretroviral therapy (ART), HIV continues to exert a significant burden on public health [2]. The virus's capacity to compromise the immune system leads to a spectrum of infections and associated complications, underscoring the critical need for a deeper understanding of HIV pathogenesis and its clinical ramifications [3].

HIV predominantly targets the immune system, with a particular emphasis on CD4+ T lymphocytes, which are crucial for orchestrating the body’s immune responses [4]. The progressive depletion of these cells by the virus impairs the immune system's ability to combat infections, thereby increasing susceptibility to opportunistic infections and other diseases [2]. Concurrently, HIV infection induces persistent immune activation, characterized by sustained inflammation that persists even in the presence of effective ART [3]. This chronic inflammatory state is implicated in the development of non-AIDS-related comorbidities, such as cardiovascular disease and accelerated aging [4].

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24AUG813

Additionally, HIV is linked to various hematological abnormalities, including anemia, thrombocytopenia, and leukopenia [1]. These hematological disorders result from both the direct effects of the virus on hematopoiesis and secondary factors such as chronic inflammation and ART-related side effects [2]. The clinical implications of these hematological conditions are substantial, as they not only serve as indicators of disease severity but also exacerbate the overall health challenges faced by individuals living with HIV [3]. This review provides a comprehensive analysis of the complications associated with HIV, with a focus on immune dysfunction and hematological abnormalities. By elucidating the underlying biological mechanisms, exploring the clinical consequences, and evaluating current therapeutic approaches, this article aims to enhance our understanding of these intricate interactions and inform future research and treatment strategies.

II. LITERATURE REVIEW

A. HIV and Immune System Dysfunction

HIV, or Human Immunodeficiency Virus, is a retrovirus that causes significant immune system deterioration by primarily targeting CD4+ T lymphocytes, a subset of white blood cells essential for orchestrating the body's immune response. Since its discovery in the early 1980s, HIV has become a global health crisis, with millions of people affected worldwide. The profound impact of HIV on the immune system is primarily due to its unique ability to target and destroy CD4+ T cells, leading to a cascade of immunological failures that culminate in Acquired Immunodeficiency Syndrome (AIDS) [5].

B. The Biology of HIV

To understand how HIV causes immune system dysfunction, it is crucial to examine its biology. HIV is an RNA virus that belongs to the lentivirus family, a subgroup of retroviruses known for their slow replication cycle. The virus contains two copies of single-stranded RNA as its genetic material, surrounded by a protein capsid and an outer lipid envelope derived from the host cell membrane. The envelope contains glycoproteins, such as gp120 and gp41, which play a vital role in the virus's ability to infect host cells [5].

HIV primarily infects cells that express the CD4 molecule on their surface. CD4 is a glycoprotein found on the surface of immune cells, including T helper cells, macrophages, and dendritic cells. The gp120 protein on the surface of HIV binds to the CD4 receptor, facilitating viral attachment to the host cell. Following this initial attachment, gp120 undergoes a conformational change, allowing it to interact with a co-receptor, either CCR5 or CXCR4, depending on the strain of HIV. This interaction is critical for the fusion of the viral envelope with the host cell membrane, mediated by the gp41 protein, which facilitates the entry of the viral RNA into the host cell [5].

Once inside the host cell, the viral RNA is reverse-transcribed into DNA by the enzyme reverse transcriptase, a process that is error-prone and leads to high genetic variability in the virus. The newly synthesized viral DNA is then integrated into the host cell's genome by the enzyme integrase, allowing the virus to hijack the host cell's machinery to produce new viral particles. The integrated viral DNA, known as a provirus, can remain latent for an extended period, evading detection by the immune system. Alternatively, it can become transcriptionally active, leading to the production of new viral particles that bud from the host cell and go on to infect other CD4+ cells [5].

C. HIV-Induced CD4+ T Cell Depletion

The depletion of CD4+ T cells is a hallmark of HIV infection and a major contributor to immune system dysfunction. CD4+ T cells, also known as helper T cells, play a central role in the immune response by coordinating the activity of other immune cells, such as CD8+ cytotoxic T lymphocytes, B cells, and macrophages. The loss of CD4+ T cells disrupts this coordination, leading to a weakened immune response and increased susceptibility to opportunistic infections and certain cancers [6].



Fig 1 Mechanism of HIV entry into CD4+ T cells, highlighting the role of CD4 receptors and co-receptors CCR5/CXCR4.

➢ *Several Mechanisms Contribute to the Depletion of CD4+ T cells in HIV Infection:*

- *Direct Viral Killing of Infected Cells:*

HIV directly kills CD4+ T cells through various mechanisms. Once the virus has entered the cell and integrated its genome, the production of viral proteins can induce cell death. This process, known as pyroptosis, is a

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24AUG813

form of programmed cell death associated with inflammation. HIV-infected CD4+ T cells can also undergo apoptosis, another form of programmed cell death, in response to viral replication and the expression of viral proteins on the cell surface [6].

- *Chronic Immune Activation:*

HIV infection leads to a state of chronic immune activation, characterized by the continuous activation of the immune system, even in the absence of active infection. This persistent activation is driven by several factors, including the presence of viral RNA and proteins, the translocation of microbial products from the gut into the bloodstream, and the production of pro-inflammatory cytokines. Chronic immune activation leads to the exhaustion and eventual death of CD4+ T cells, contributing to their depletion [6].

- *Immune-Mediated Destruction:*

In addition to direct viral killing, HIV-infected CD4+ T cells are targeted for destruction by the immune system. CD8+ cytotoxic T lymphocytes, which recognize and kill infected cells, play a significant role in this process. However, chronic activation and exhaustion of CD8+ T cells impair their ability to control the virus effectively, leading to the persistence of infected cells [7].

- *Bystander Apoptosis:*

HIV infection also induces apoptosis in uninfected CD4+ T cells, a phenomenon known as bystander apoptosis. This occurs when the immune system mistakenly targets uninfected cells due to the inflammatory environment created by chronic immune activation. The release of pro-inflammatory cytokines, such as TNF-α and IFN-γ, contributes to the induction of apoptosis in these bystander cells [7].

- *Destruction of Lymphoid Tissue:*

HIV causes significant damage to lymphoid tissues, particularly in the gut-associated lymphoid tissue (GALT), where a large proportion of the body's CD4+ T cells reside. The destruction of these tissues leads to the loss of a significant number of CD4+ T cells early in infection, contributing to the overall depletion of these cells in the body [7].

➢ *Chronic Immune Activation in HIV Infection*

Chronic immune activation is a defining feature of HIV infection and a major driver of disease progression. Even in individuals receiving effective ART, which suppresses viral replication to undetectable levels, immune activation persists. This chronic state of immune activation is associated with several adverse outcomes, including accelerated aging, increased risk of cardiovascular disease, neurocognitive decline, and other non-AIDS-related comorbidities [7].

➢ *Mechanisms of Chronic Immune Activation:*

- *Persistent Low-Level Viral Replication:*

Despite effective ART, low-level viral replication can occur in reservoirs, such as latently infected CD4+ T cells and macrophages. These reservoirs serve as a source of viral antigens that continuously stimulate the immune system, contributing to chronic immune activation [8].

- *Microbial Translocation:*

HIV causes significant damage to the mucosal barriers of the gut, leading to increased permeability and the translocation of microbial products, such as lipopolysaccharide (LPS), into the bloodstream. These microbial products act as potent activators of the immune system, driving chronic inflammation and immune activation [9].

- *Production of Pro-Inflammatory Cytokines:*

HIV infection leads to the dysregulation of cytokine production, with increased levels of pro-inflammatory cytokines, such as IL-6, TNF-α, and IFN-γ. These cytokines contribute to the activation of the immune system and the induction of chronic inflammation, further driving the depletion of CD4+ T cells and the exhaustion of CD8+ T cells [9].

- *Co-Infections:*

Co-infections with other viruses, such as cytomegalovirus (CMV) and hepatitis C virus (HCV), are common in individuals with HIV and contribute to chronic immune activation. These co-infections lead to the activation of additional immune pathways and the production of pro-inflammatory cytokines, exacerbating the inflammatory environment in the body [10].

- *Immune Checkpoint Dysregulation:*

Immune checkpoints, such as PD-1 and CTLA-4, are molecules that regulate the immune response by preventing overactivation. In HIV infection, these checkpoints are dysregulated, leading to the chronic activation and eventual exhaustion of immune cells, particularly CD8+ T cells. This exhaustion impairs the ability of the immune system to control HIV and other infections effectively [11].

➢ *Consequences of Chronic Immune Activation:*

- *Immune Exhaustion:*

Chronic immune activation leads to the exhaustion of T cells, particularly CD8+ T cells, which are crucial for controlling viral infections. Exhausted T cells lose their ability to proliferate and produce cytokines, rendering them less effective in clearing infected cells. This exhaustion is characterized by the upregulation of inhibitory receptors, such as PD-1, and the downregulation of co-stimulatory molecules [11].

- *Tissue Damage:*

The persistent activation of the immune system leads to tissue damage, particularly in lymphoid organs, such as the spleen and lymph nodes. This damage impairs the ability of these organs to function properly, further weakening the immune system [12].

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24AUG813

- *Increased Susceptibility to Infections:*

The depletion of CD4+ T cells and the exhaustion of CD8+ T cells leave individuals with HIV more susceptible to opportunistic infections, such as Pneumocystis pneumonia, tuberculosis, and cytomegalovirus retinitis. These infections are often severe and can be life-threatening in individuals with advanced HIV disease [12].

- *Accelerated Aging:*

Chronic immune activation is associated with accelerated aging in individuals with HIV. This is evidenced by the premature onset of age-related comorbidities, such as cardiovascular disease, osteoporosis, and neurocognitive decline. The mechanisms underlying this accelerated aging are complex and likely involve a combination of chronic inflammation, immune exhaustion, and the direct effects of HIV on cellular function [12].

- *Increased Risk of Non-AIDS-Related Comorbidities:*

In addition to opportunistic infections, chronic immune activation is associated with an increased risk of non-AIDS-related comorbidities, such as cardiovascular disease, kidney disease, and certain cancers. These conditions are thought to result from the persistent inflammatory environment in the body, which contributes to the development of atherosclerosis, renal dysfunction, and tumorigenesis [13].

D. HIV's Impact on Different Immune Cells

While CD4+ T cells are the primary targets of HIV, the virus also affects other immune cells, including CD8+ cytotoxic T cells, B cells, natural killer (NK) cells, and monocytes/macrophages. Each of these cell types plays a crucial role in the immune response, and their dysfunction contributes to the overall immune deficiency observed in HIV infection [13].



Fig 2 The impact of HIV on various immune cells, including CD4+ T cells, CD8+ T cells, B cells, and NK cells, showing downstream effects on immune function.

➢ *CD3+ T Cells:*

CD3+ T cells include both CD4+ and CD8+ T cells, which are critical for adaptive immunity. The CD3 complex is a component of the T cell receptor (TCR), which is essential for recognizing antigens presented by other cells. HIV infection leads to the dysregulation of CD3+ T cells, resulting in impaired T cell signaling and function [13].

- *CD3+CD4+ T Cells:*

As previously discussed, HIV directly targets CD4+ T cells, leading to their depletion and the subsequent collapse of the immune system. The loss of CD4+ T cells disrupts the coordination of the immune response, making it difficult for the body to mount an effective defense against infections [13].

- *CD3+CD8+ T Cells:*

CD8+ T cells are responsible for killing infected cells, including those harboring HIV. However, in the context of chronic HIV infection, these cells become functionally exhausted. This exhaustion is characterized by reduced cytokine production, impaired proliferation, and decreased cytotoxic activity. The upregulation of inhibitory receptors, such as PD-1 and CTLA-4, further contributes to the dysfunction of CD8+ T cells. Despite these impairments, CD8+ T cells play a critical role in controlling viral replication, particularly during the early stages of infection [13].

- *CD19+ B Cells:*

B cells, marked by CD19 expression, are responsible for producing antibodies that neutralize pathogens. In HIV infection, B cell function is significantly impaired, leading to dysregulated antibody responses and increased susceptibility to infections [14].

- *Polyclonal B Cell Activation:*

HIV infection induces polyclonal B cell activation, resulting in the production of large quantities of non-specific antibodies. This dysregulated response reduces the effectiveness of the immune system in targeting specific pathogens and contributes to the hypergammaglobulinemia observed in individuals with HIV [15].

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24AUG813

- *Impaired Germinal Center Function:*

Germinal centers are specialized structures within lymphoid tissues where B cells undergo maturation and differentiation into memory B cells and plasma cells. HIV infection disrupts the formation and function of germinal centers, leading to impaired B cell maturation and reduced production of high-affinity antibodies. This disruption is primarily due to the depletion of follicular helper T cells (Tfh), a subset of CD4+ T cells that provide essential signals for B cell maturation [16].

- *Increased Risk of B Cell Lymphomas:*

Individuals with HIV are at an increased risk of developing B cell lymphomas, a type of cancer that originates from B cells. The chronic activation and dysregulation of B cells, combined with immune suppression, create an environment conducive to the development of these malignancies [16].

- *Reduced Vaccine Efficacy:*

The impaired function of B cells in HIV-infected individuals reduces the efficacy of vaccines, as the production of protective antibodies is compromised. This presents a significant challenge for immunization strategies in this population, particularly for vaccines against common pathogens such as influenza and pneumococcus [17].

➢ *CD56+ Natural Killer (NK) Cells:*

NK cells, characterized by the expression of CD56, are a crucial component of the innate immune system, responsible for the rapid elimination of infected or transformed cells without prior sensitization. HIV infection impairs the function of NK cells, contributing to immune dysfunction and the persistence of the virus [18].

- *Altered NK Cell Subset Distribution:*

HIV infection leads to changes in the distribution of NK cell subsets, with a decrease in the CD56^bright^ NK cells, which are primarily responsible for cytokine production, and an increase in the CD56^dim^ NK cells, which have greater cytotoxic activity. However, the overall cytotoxic function of NK cells is diminished, reducing their ability to eliminate HIV-infected cells [18].

- *Impaired Cytotoxicity:*

The cytotoxic activity of NK cells is impaired in HIV infection, partly due to the downregulation of activating receptors, such as NKG2D, on the surface of NK cells. Additionally, the chronic activation and inflammatory environment in HIV infection contribute to the functional exhaustion of NK cells, similar to what is observed in CD8+ T cells [18].

- *Decreased Production of Cytokines:*

NK cells produce cytokines, such as IFN-γ and TNF-α, that play a critical role in controlling viral infections. In HIV infection, the production of these cytokines is reduced, further compromising the ability of NK cells to control viral replication and contribute to the overall immune response [18].

- *HIV Evasion of NK Cell-Mediated Killing:*

HIV has evolved several mechanisms to evade NK cell-mediated killing. For example, the virus downregulates the expression of ligands for activating NK cell receptors on the surface of infected cells, making them less susceptible to NK cell-mediated lysis. Additionally, HIV can upregulate the expression of inhibitory ligands, such as HLA-E, which bind to inhibitory receptors on NK cells and suppress their activity [18].

➢ *Monocytes/Macrophages:*

Monocytes and macrophages are components of the innate immune system and play a critical role in the early response to infection. These cells are also important in antigen presentation, the process by which foreign particles are presented to T cells, triggering an adaptive immune response. HIV affects monocytes and macrophages in several ways, contributing to immune dysfunction [19].

- *HIV Infection of Monocytes and Macrophages:*

Unlike CD4+ T cells, which are killed by HIV, monocytes and macrophages can be infected by the virus but often survive, becoming reservoirs for HIV. These cells harbor the virus and can disseminate it throughout the body, particularly to tissues where HIV is difficult to eradicate, such as the central nervous system [19].

- *Altered Cytokine Production:*

HIV infection alters the cytokine production of monocytes and macrophages, leading to a pro-inflammatory state. This chronic inflammation contributes to tissue damage and the development of HIV-associated comorbidities, such as cardiovascular disease [19].

- *Impaired Phagocytosis:*

Phagocytosis, the process by which macrophages engulf and digest pathogens, is impaired in HIV infection. This impairment reduces the ability of the immune system to clear infections, contributing to the increased susceptibility to opportunistic infections observed in individuals with HIV [20].

- *Role in Chronic Immune Activation:*

Monocytes and macrophages play a key role in the chronic immune activation observed in HIV infection. These cells produce pro-inflammatory cytokines, such as IL-6 and TNF-α, that contribute to the persistent activation of the immune system. Additionally, infected macrophages can present HIV antigens to T cells, driving their activation and contributing to immune exhaustion [20].

E. HIV-Associated Hematological Complications

HIV infection is associated with a range of hematological abnormalities, including anemia, thrombocytopenia, leukopenia, and lymphopenia. These complications contribute to the morbidity and mortality associated with HIV and can complicate the management of the disease [21].

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24AUG813

➢ *Anemia in HIV*

Anemia is a common complication of HIV infection, particularly in individuals with advanced disease. It is associated with increased mortality and reduced quality of life. The prevalence of anemia in HIV-infected individuals varies widely, depending on the population studied and the stage of the disease, but it is estimated to affect 20-70% of people with HIV [21].

➢ *Causes of Anemia in HIV:*

- *Direct Viral Effects on Bone Marrow:*

HIV can directly infect bone marrow progenitor cells, leading to impaired erythropoiesis, the process by which red blood cells are produced. The infection of these progenitor cells can lead to their apoptosis or dysfunction, resulting in reduced red blood cell production [21].

- *Chronic Inflammation and Anemia of Chronic Disease (ACD):*

Chronic inflammation in HIV infection contributes to anemia through the development of anemia of chronic disease (ACD). In ACD, the inflammatory cytokines produced during chronic immune activation, such as IL-6, lead to increased production of hepcidin, a hormone that inhibits iron absorption and sequestration in macrophages. This results in reduced iron availability for erythropoiesis, leading to anemia [22].

- *Nutritional Deficiencies:*

Nutritional deficiencies, particularly of iron, vitamin B12, and folate, are common in individuals with HIV and contribute to the development of anemia. Malabsorption due to HIV-associated enteropathy and the side effects of ART, such as gastrointestinal disturbances, can exacerbate these deficiencies [23].

- *Bone Marrow Suppression by ART:*

Certain antiretroviral drugs, particularly zidovudine (AZT), can cause bone marrow suppression, leading to reduced production of red blood cells and anemia. The mechanism of this suppression is thought to involve mitochondrial toxicity and the inhibition of DNA synthesis in bone marrow progenitor cells [23].

- *Opportunistic Infections:*

Opportunistic infections, such as Mycobacterium avium complex (MAC) and Parvovirus B19, can infect the bone marrow and impair erythropoiesis, leading to anemia. These infections are more common in individuals with advanced HIV disease and contribute to the severity of anemia in this population [23].

➢ *Clinical Consequences of Anemia in HIV:*

Anemia in HIV is associated with several adverse outcomes, including increased mortality, reduced physical function, and impaired cognitive function. It also complicates the management of HIV, as severe anemia may limit the use of certain ARTs, such as AZT, which can exacerbate the condition. The presence of anemia also increases the risk of other comorbidities, such as cardiovascular disease, due to the increased workload on the heart [24].



Fig 3 Prevalence of Anemia Among HIV-Infected Individuals at Different Stages.

➢ *Thrombocytopenia in HIV*

Thrombocytopenia, defined as a platelet count of less than 150,000/μL, is a common hematological complication of HIV infection, affecting 10-30% of individuals with HIV. It is associated with an increased risk of bleeding, particularly in individuals with severe thrombocytopenia (platelet count <20,000/μL) [25].

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24AUG813



Fig 4 Mechanisms leading to thrombocytopenia in HIV, including direct viral effects on megakaryocytes and immune-mediated destruction of platelets.

➢ *Causes of Thrombocytopenia in HIV:*

- *Immune-Mediated Destruction of Platelets:*

HIV-associated thrombocytopenia is often immune-mediated, similar to immune thrombocytopenic purpura (ITP). The immune system produces antibodies against platelets, leading to their destruction in the spleen. The mechanism underlying this immune response is not fully understood but is thought to involve the formation of immune complexes containing HIV antigens and anti-platelet antibodies [26].

- *Direct Viral Effects on Megakaryocytes:*

HIV can directly infect megakaryocytes, the bone marrow cells responsible for producing platelets. This infection can lead to impaired platelet production, contributing to thrombocytopenia. The virus may also induce apoptosis in these cells, further reducing platelet production [26].

- *Increased Platelet Destruction by ART:*

Certain antiretroviral drugs, particularly zidovudine (AZT), can cause bone marrow suppression, leading to reduced platelet production and thrombocytopenia. Additionally, ART can induce immune reconstitution inflammatory syndrome (IRIS), a condition characterized by an exaggerated immune response to opportunistic infections, which can exacerbate thrombocytopenia [27].

- *HIV-Associated Malignancies:*

HIV-infected individuals are at increased risk of developing certain malignancies, such as non-Hodgkin lymphoma and Kaposi's sarcoma, which can infiltrate the bone marrow and impair platelet production. Additionally, the treatments for these malignancies, such as chemotherapy, can further reduce platelet counts [27].

➢ *Clinical Consequences of Thrombocytopenia in HIV:*

Thrombocytopenia in HIV is associated with an increased risk of bleeding, particularly mucocutaneous bleeding, such as petechiae, purpura, and epistaxis. Severe thrombocytopenia can lead to life-threatening hemorrhages, particularly in the gastrointestinal tract or central nervous system. The presence of thrombocytopenia also complicates the management of HIV, as certain ARTs and treatments for opportunistic infections may exacerbate the condition [28].

➢ *Leukopenia and Lymphopenia in HIV*

Leukopenia, defined as a white blood cell count of less than 4,000/µL, and lymphopenia, defined as a lymphocyte count of less than 1,500/µL, are common hematological abnormalities in HIV infection. These conditions are associated with an increased risk of infections and are indicative of advanced immune system dysfunction [28].

➢ *Causes of Leukopenia and Lymphopenia in HIV:*

- *Direct Viral Effects on Bone Marrow Progenitor Cells:*

HIV can infect bone marrow progenitor cells, leading to impaired production of white blood cells and lymphocytes. This infection can result in the apoptosis or dysfunction of these progenitor cells, contributing to leukopenia and lymphopenia [29].

- *Chronic Immune Activation:*

Chronic immune activation in HIV infection leads to the exhaustion and eventual depletion of immune cells, particularly lymphocytes. The persistent activation of the

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24AUG813

immune system drives the turnover of lymphocytes, leading to their depletion over time [29].

- *Bone Marrow Suppression by ART:*

Certain antiretroviral drugs, particularly zidovudine (AZT), can cause bone marrow suppression, leading to reduced production of white blood cells and lymphocytes. This suppression may result from mitochondrial toxicity and the inhibition of DNA synthesis in bone marrow progenitor cells [30].

- *Opportunistic Infections:*

Opportunistic infections, such as cytomegalovirus (CMV) and Mycobacterium avium complex (MAC), can infect the bone marrow and impair the production of white blood cells and lymphocytes, leading to leukopenia and lymphopenia. These infections are more common in individuals with advanced HIV disease and contribute to the severity of these conditions [30].

➢ *Clinical Consequences of Leukopenia and Lymphopenia in HIV:*

Leukopenia and lymphopenia in HIV are associated with an increased risk of infections, particularly opportunistic infections, such as Pneumocystis pneumonia, tuberculosis, and cytomegalovirus retinitis. These infections are often severe and can be life-threatening in individuals with advanced HIV disease. The presence of leukopenia and lymphopenia also complicates the management of HIV, as certain ARTs and treatments for opportunistic infections may exacerbate these conditions [30].

III. CONCLUSION

HIV continues to pose a substantial global health challenge, despite significant progress in antiretroviral therapy (ART). The virus's ability to specifically target and deplete CD4+ T cells leads to profound immune system dysfunction, which is exacerbated by chronic immune activation. This disruption of immune function not only increases susceptibility to opportunistic infections but also contributes to the development of non-AIDS-related comorbidities, such as cardiovascular disease and accelerated aging.

Hematological abnormalities, including anemia, thrombocytopenia, leukopenia, and lymphopenia, further complicate the clinical management of HIV. These conditions arise from a combination of direct viral effects, chronic inflammation, and side effects of ART. Understanding the mechanisms underlying these hematological issues is crucial for optimizing patient management and mitigating their impact on health outcomes.

Addressing these challenges requires a multi-faceted approach, including improved diagnostic methods, refined therapeutic strategies, and ongoing research. By enhancing our comprehension of HIV-related complications and their underlying processes, we can better support individuals living with HIV and work towards more effective interventions and improved quality of life.

REFERENCES

[1]. ***UNAIDS. (2023).*** *Global HIV & AIDS statistics — Fact sheet. UNAIDS. Retrieved from https://www.unaids.org/en/resources/fact-sheet*

[2]. ***World Health Organization. (2023).*** *HIV/AIDS. WHO. Retrieved from https://www.who.int/news-room/fact-sheets/detail/hiv-aids*

[3]. ***Deeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015).*** *HIV infection. Nature Reviews Disease Primers, 1, 15035. https://doi.org/10.1038/nrdp.2015.35*

[4]. ***Gupta, R. K., Abdul-Jawad, S., McCoy, L. E., Mok, H. P., Peppa, D., Salgado, M., ... & Olavarria, E. (2019).*** *HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature, 568(7751), 244-248. https://doi.org/10.1038/s41586-019-1027-4*

[5]. ***Sundquist, W. I., & Kräusslich, H. G. (2012).*** *HIV-1 assembly, budding, and maturation. Cold Spring Harbor Perspectives in Medicine, 2(7), a006924. https://doi.org/10.1101/cshperspect.a006924*

[6]. ***Doitsh, G., Galloway, N. L., Geng, X., Yang, Z., Monroe, K. M., Zepeda, O., ... & Greene, W. C. (2014).*** *Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature, 505(7484), 509-514. https://doi.org/10.1038/nature12940*

[7]. ***Appay, V., & Sauce, D. (2008).*** *Immune activation and inflammation in HIV-1 infection: causes and consequences. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 214(2), 231-241. https://doi.org/10.1002/path.2276*

[8]. ***Chun, T. W., Stuyver, L., Mizell, S. B., Ehler, L. A., Mican, J. A., Baseler, M., ... & Fauci, A. S. (1997).*** *Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences, 94(24), 13193-13197. https://doi.org/10.1073/pnas.94.24.13193*

[9]. ***Brenchley, J. M., Price, D. A., Schacker, T. W., Asher, T. E., Silvestri, G., Rao, S., ... & Douek, D. C. (2006).*** *Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Medicine, 12(12), 1365-1371. https://doi.org/10.1038/nm1511*

[10]. ***Sandler, N. G., & Douek, D. C. (2012).*** *Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nature Reviews Microbiology, 10(9), 655-666. https://doi.org/10.1038/nrmicro2848*

[11]. ***McGary, C. S., Deleage, C., Harper, J., Micci, L., Ribeiro, S. P., Paganini, S., ... & Silvestri, G. (2017).*** *CTLA-4+PD-1− memory CD4+ T cells critically contribute to viral persistence in antiretroviral therapy-suppressed, SIV-infected rhesus macaques. Immunity, 47(4), 776-788.e5. https://doi.org/10.1016/j.immuni.2017.09.018*

[12]. ***Deeks, S. G. (2011).*** *HIV infection, inflammation, immunosenescence, and aging. Annual Review of Medicine, 62, 141-155. https://doi.org/10.1146/annurev-med-042909-093756*

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24AUG813

[13]. ***Appay, V., & Rowland-Jones, S. L. (2002).*** *Premature ageing of the immune system: the cause of AIDS? Trends in Immunology, 23(12), 580-585 https://doi.org/10.1016/S1471-4906(02)02338-4*

[14]. ***Moir, S., Malaspina, A., & Fauci, A. S. (2011).*** *Prospects for an HIV vaccine: leading B cells down the right path. Nature Structural & Molecular Biology, 18(2), 131-132. https://doi.org/10.1038/nsmb.2194*

[15]. ***Moir, S., Malaspina, A., Ogwaro, K. M., Donoghue, E. T., Hallahan, C. W., Ehler, L. A., ... & Fauci, A. S. (2001).*** *HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proceedings of the National Academy of Sciences, 98(18), 10362-10367. https://doi.org/10.1073/pnas.181347898*

[16]. ***Titanji, K., Chiodi, F., Bellocco, R., Schepis, D., Osorio, L., Vendrell, A., ... & Biberfeld, P. (2005).*** *Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS, 19(17), 1947-1955. https://doi.org/10.1097/01.aids.0000191231.54170.89*

[17]. ***Plotkin, S. A. (2008).*** *Vaccines: correlates of vaccine-induced immunity. Clinical Infectious Diseases, 47(3), 401-409. https://doi.org/10.1086/589862*

[18]. ***Alter, G., & Altfeld, M. (2011).*** *NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. Journal of Internal Medicine, 269(1), 29-42. https://doi.org/10.1111/j.1365-2796.2008.02045.x*

[19]. ***Wallet, M. A., Rodriguez, C. A., Yin, L., Saporta, S., Chinratanapisit, S., Hou, W., ... & Chang, L. J. (2010).*** *Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS, 24(9), 1281-1290. https://doi.org/10.1097/QAD.0b013e328339e228*

[20]. ***Ellis, R. J., Caligiuri, M., & McCune, J. M. (2007).*** *Immunopathogenesis of HIV infection. Immunological Reviews, 218(1), 29-44. https://doi.org/10.1146/annurev.micro.50.1.825*

[21]. ***Belperio, P. S., & Rhew, D. C. (2004).*** *Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. The American Journal of Medicine, 116(Suppl 7A), 27S-43S. https://doi.org/10.1016/j.amjmed.2003.12.010*

[22]. ***Weiss, G., & Goodnough, L. T. (2005).*** *Anemia of chronic disease. New England Journal of Medicine, 352(10), 1011-1023. https://doi.org/10.1056/NEJMra041809*

[23]. ***Sullivan, P. S., Hanson, D. L., Chu, S. Y., Jones, J. L., & Ward, J. W. (1998).*** *Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood, 91(1), 301-308. https://doi.org/10.1182/blood.V91.1.301*

[24]. ***Semba, R. D., Shah, N., Klein, R. S., Mayer, K. H., Schuman, P., Vlahov, D., & Womens Interagency HIV Study. (2002).*** *Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of HIV-infected and uninfected women. Clinical Infectious Diseases, 34(2), 260-266. https://doi.org/10.1086/338151*

[25]. *Awamura T, Nakasone ES, Gangcuangco LM, Subia NT, Bali A-J, Chow DC, et al.* ***Title of the article****. Journal Name. 2023 Nov; 13(11): 1608. https://doi.org/10.3390/biom13111608.*

[26]. *Talargia F, Getacher L. Thrombocytopenia and associated factors among HIV-infected patients in pre- and post-anti-retroviral therapy, North East Ethiopia. Journal of Blood Medicine. 2021; 12: 741-748. https://doi.org/10.2147/JBM.S323086*

[27]. Phillips AN, Lazzarin A, Gonzales-Lahoz J, Lundgren JD, Johnson AM; The AIDS in Europe Study Group. Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. J Clin Epidemiol. 1996 Nov;49(11):1253-1258. DOI: https://doi.org/10.1016/S0895-4356(96)00216-8.

[28]. **Redig, A. J., & Berliner, N. (2013).** Pathogenesis and clinical implications of HIV-related anemia in 2013. *Hematology/Oncology Clinics*, 27(2), 337-352. https://doi.org/10.1182/asheducation-2013.1.377

[29]. Tilahun M, Gedefie A, Ebrahim E, Seid A, Ali A, Shibabaw A, Belete MA, Fiseha M, Tesfaye M, Ebrahim H, Abera A. Immuno-haematological abnormalities of HIV-infected patients before and after initiation of highly active antiretroviral therapy in the antiretroviral therapy clinics of six health facilities at Dessie Town, Northeast Ethiopia. J Blood Med. 2022;13:243-253. DOI: https://doi.org/10.2147/JBM.S364700.

[30]. **Mocroft, A., Lifson, A. R., Touloumi, G., Baxter, J., Clumeck, N., D'Arminio Monforte, A., ... & Ledergerber, B. (1999).** Haemoglobin and anaemia in the SMART study: associations with clinical and laboratory parameters. *Antiviral Therapy*, 14(8), 1097-1104. https://doi.org/10.3851/IMP1746